Junevity

San Francisco UCSF spinout that uses ML to pick transcription-factor targets and drugs them with twice-yearly siRNA; lead in T2D/obesity.

1. Core Product / Service

Junevity's RESET platform combines human disease omics, genetic associations and machine learning. Its purpose is to find transcription factors whose activity drives a cell's damaged state; the company then silences them with siRNA to "reset" cells to health [1][3]. The underlying research came from co-founder Janine Sengstack's work at UCSF and is exclusively licensed [1].

The lead candidate JUN_01 targets a confidential transcription factor linked to metabolic dysfunction, insulin signaling and appetite. It is being developed for type 2 diabetes and obesity, dosed once every six months [3]. The company reports preclinical improvements in blood glucose and insulin sensitivity, weight loss with preserved lean mass, and resistance to weight regain; these are company data [3]. JUN_01 is in IND-enabling work, with first-in-human studies planned for the second half of 2026 [3]. Early neurodegeneration programs are planned [3].

Wet lab. Undisclosed. No lab location, area, job postings or CRO partners were found. A database lists a San Francisco address and roughly 13 employees; both are unverified. AI is used for target selection, and siRNA is a mature modality with an established outsourced chemistry and toxicology supply chain. It is therefore plausible that most synthesis and IND-enabling studies are outsourced, but this is an inference, not a disclosure.

2. Target Users & Pain Points

Patients: people with type 2 diabetes and obesity who want durable metabolic control and weight maintenance without weekly injections.
Pain addressed: incretin drugs need frequent dosing and weight often returns after stopping. A twice-yearly siRNA acting on a regulator upstream of many pathways is the company's alternative [3].

3. Competitive Landscape

Player	Approach	Vs. Junevity
kailera-therapeutics / verdiva-bio	Next-generation incretins	Established mechanism; frequent dosing
Alnylam, Arrowhead	siRNA metabolic programs	Mature siRNA platforms with known targets
newlimit	Transcription-factor reprogramming via mRNA-LNP	Same "cell reset" idea, delivered as gene expression rather than silencing
retro-biosciences / altos-labs	Rejuvenation biology	Much larger capital; longevity framing

4. Unique Observations

Moderate AI weighting. AI selects targets; the drug format, siRNA, is well proven. Junevity is therefore less "AI-native" than de novo design companies, but its clinical risk is concentrated in target biology rather than in an unproven modality.
Fast to clinic for its size. With a $20M seed, the company plans first-in-human about three years after founding. That is faster than most US AI biotechs founded in 2023 or later, apart from the much better-funded Mirador.
Longevity framing, metabolic first indication. The company launched as a "cell reset for longevity" story, but its first indication is a conventional, large metabolic market [1][3].

5. Financials / Funding

Round	Date	Amount	Investors
Seed	2025-02-13	$10M	Goldcrest Capital, Godfrey Capital (leads) [1]
Seed expansion	2025-12	$10M (seed total $20M)	Goldcrest, Godfrey [2][3]

Total: $20M [2]. The CEO said the company was not actively fundraising when the expansion came in [2].

6. People & Relationships

Co-founder & CEO: John Hoekman (co-founder of Impel Pharmaceuticals) [3].
Co-founder & CSO: Janine Sengstack (UCSF research basis) [1].
COO: Rob Cahill [1]. One profile also lists Hao Li as a founder (unverified).
Origin: UCSF spinout, founded 2023 [3][4].
Peers: newlimit, retro-biosciences, kailera-therapeutics.

Sources

[1] Junevity launch press release via Nasdaq/BusinessWire (2025-02-13; accessed 2026-10-14)
[2] Junevity press release via BioSpace, seed expanded to $20M (2025-12; accessed 2026-10-14)
[3] Pulse 2.0, "Junevity seed round expanded to $20 million" (2025-12-11; accessed 2026-10-14)
[4] Lifespan.io launch coverage; Dealroom profile (accessed 2026-10-14)